Last reviewed · How we verify

NCT06600282

Bioequivalence of Two Formulations of Parecoxib in Healthy Volunteers Under Fasting Conditions

Not yet recruiting Phase 4 Last updated 20 September 2024
What this trial tests

Phase 4 trial testing Parecoxib in Post-operative Pain in 14 participants. Not yet recruiting.

Timeline
1 October 2024
Primary endpoint
30 November 2024
30 December 2024

Quick facts

Lead sponsorYung Shin Pharm. Ind. Co., Ltd.
PhasePhase 4
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeother
Enrollment14
Start date1 October 2024
Primary completion30 November 2024
Estimated completion30 December 2024
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Yung Shin Pharm. Ind. Co., Ltd. — full company profile →

Who can join

Adults 20 to 45, any sex, with Post-operative Pain or Bioequivalence Study in Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of parecoxib after intravenous bolus of parecoxib in healthy volunteers under fasting conditions

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Parecoxib

Trials testing the same drug.

Other recruiting trials for Post-operative Pain

Currently open trials in the same condition.

Other Yung Shin Pharm. Ind. Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06600282.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing